Otsuka Pharmaceutical has accelerated FDA approval for Voyxact to reduce proteinuria in adults with primary IgAN at disease ...

The proportion of children receiving a second dose of the MMR vaccine is still below the threshold to stop viral transmission ...

In 2024, over half of patients found to have HIV in Europe received a late diagnosis, which is often associated with poor ...

Not long after cutting its sales forecast for 2025, Valneva has decided to decrease its operational footprint in France by ...

With an eye on 2026, the healthcare editorial team reflects on key takeaways and trends from recent pharma conferences.

Developed by UCL spinout Autolus, Aucatzyl will be launched imminently across England and Wales. A UK-developed cell therapy ...

The UK MHRA has granted approval to Roche Products’ inavolisib to treat adults diagnosed with HR-positive, HER2-negative ...

Eydenzelt is subjecting Eylea to further biosimilar erosion, though Regeneron hopes to offset this with two new approvals for Eylea HD.

As the US Centers for Medicare and Medicaid Services (CMS) has released the new prices for 15 drugs that have been added to ...

While the Phase III results confirm prior analyst sentiments, a KOL notes that GLP-1RAs could still show potential in the ...

Gilead now own the rights to Sprint's preclinical oncology immunotherapy programme, which targets the novel cancer target, ...

This licensing deal falls under SK's wider ploy to harness the growing promise of radiopharmaceuticals within the oncology ...